TY - JOUR T1 - Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells JF - Anticancer Research JO - Anticancer Res SP - 5049 LP - 5056 DO - 10.21873/anticanres.12824 VL - 38 IS - 9 AU - TOSHIHARU MURAKAMI AU - TSUTOMU NAKAZAWA AU - ATSUSHI NATSUME AU - FUMIHIKO NISHIMURA AU - MITSUTOSHI NAKAMURA AU - RYOSUKE MATSUDA AU - KOJI OMOTO AU - YOSHITAKA TANAKA AU - YOUICHI SHIDA AU - YOUNG-SOO PARK AU - YASUSHI MOTOYAMA AU - ICHIRO NAKAGAWA AU - SHUICHI YAMADA AU - KENTARO TAMURA AU - YASUHIRO TAKESHIMA AU - YOSHIAKI TAKAMURA AU - TOSHIHIKO WAKABAYASHI AU - HIROYUKI NAKASE Y1 - 2018/09/01 UR - http://ar.iiarjournals.org/content/38/9/5049.abstract N2 - Background/Aim: Natural killer (NK) cells are considered potential antitumor effector cells. The aim of this study was to establish a novel type of a chimeric antigen receptor (CAR) NK cell line (CAR-KHYG-1) specific for epidermal growth factor receptor variant III (EGFRvIII)-expressing tumors and investigate the anti-tumor activity of EGFRvIII-specific-CAR-KHYG-1 (EvCAR-KHYG-1). Materials and Methods: EvCAR-KHYG-1 was established by self-inactivated lentiviral-based transduction of the EvCAR gene and magnetic bead-based purification of EvCAR-expressing NK cells. The anti-tumor effects of EvCAR-KHYG-1 were evaluated using growth inhibition and apoptosis detection assays in glioblastoma (GBM) cell lines (EGFRvIII-expressing and non-expressing U87MG). Results: The findings demonstrated that EvCAR-KHYG-1 inhibited GBM cell-growth via apoptosis in an EGFRvIII-expressing specific manner. Conclusion: This is the first study to establish a CAR NK cell line based on the human NK cell line KHYG-1. Therapy with EvCAR-KHYG-1 may be an effective treatment option for GBM patients. ER -